Show simple item record

dc.contributor.authorMaddocks, Sarah
dc.contributor.othercmet = Sarah Maddocks
dc.date.accessioned2016-11-18T16:27:32Z
dc.date.available2016-11-18T16:27:32Z
dc.date.issued2016
dc.identifier.citationMaddocks, S. (2016) 'Novel Targets of Antimicrobial Therapies', In Kudva, I., Cornick, N., Plummer, P., Zhang, Q., Nicholson, T., Bannantine, J., Bellaire, B. (ed), Virulence Mechanisms of Bacterial Pathogens. Washington DC: ASM Press, pp. 741-752 . doi: 10.1128/microbiolspec.VMBF-0018-2015en_US
dc.identifier.urihttp://hdl.handle.net/10369/8160
dc.description.abstractDuring the golden age of antibiotic discovery, from the 1930s through the 1960s, methods of antibiotic identification relied solely on scientific observation, and while chemical analogues such as amoxicillin, derived from penicillin, continued to be developed, they retained the same mechanisms of action and hence the same bacterial targets. Moreover, there are finite modifications that can ultimately be made to “old” classes of antibiotics. Consequently, only two new classes of antibiotics have been discovered in the past 40 years, and both entered the market early in the new millennium. The advent of the genomics revolution offered a new hope for the discovery of novel antimicrobial targets. Genomic strategies were utilized to identify potential antibacterial targets, namely those that, if inhibited, resulted in the death of the bacterium. Such targets were to be present in pathogenic strains of bacteria and absent from the human host; they could include metabolic pathways, receptor ligands, and virulence traits, to name a few. Despite the abundance of targets identified using this strategy, no new antibiotics have reached the marketplace as a result of the genomics approach. However, new antimicrobials with novel targets continue to be identified and contribute to the ongoing struggle against antimicrobial resistance that threatens to return humankind to a situation comparable to the preantibiotic era.en_US
dc.language.isoenen_US
dc.publisherASM Pressen_US
dc.titleNovel targets of antimicrobial therapiesen_US
dc.typeBook chapteren_US
dc.identifier.doihttp://dx.doi.org/10.1128/microbiolspec.VMBF-0018-2015
dcterms.dateAccepted2016
rioxxterms.funderCardiff Metropolitan Universityen_US
rioxxterms.identifier.projectCardiff Metropolian (Internal)en_US
rioxxterms.versionAOen_US
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
rioxxterms.licenseref.startdate2016-11-18
rioxxterms.freetoread.startdate2100-01-01
rioxxterms.funder.project37baf166-7129-4cd4-b6a1-507454d1372een_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record